Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

Table 1 Baseline characteristics

Characteristics
Number of patients	124
Age (yr)	56 (29-83)
Sex, n (%)
Male	69 (56)
Female	55 (44)
Tumor sidedness, n (%)
Right	32 (26)
Left	92 (74)
RAS mutational status, n (%)
Wild type	64 (52)
Mutation	60 (48)
TMB status, n (%)
TMB-low	99 (80)
TMB-high	25 (20)
Status of MSI (by IHC), n (%)
MSS	120 (97)
MSI-high	4 (3)
PD-L1 status, n (%)
PD-L1 CPS ≥ 1	105 (85)
PD-L1 CPS ≥ 5	64 (52)
PD-L1 CPS ≥ 10	32 (26)
Chemotherapy backbone with bevacizumab as first-line treatment, n (%)
FOLFOX	96 (77)
FOLFIRI	28 (23)

RAS: Rat sarcoma; TMB: Tumor mutational burden; MSI: Microsatellite instability; IHC: Immunohistochemistry; MSS: Microsatellite stability; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score.